HPV cervical infections and serological status in vaccinated and unvaccinated women. Issue 51 (3rd December 2020)

• Record Type: Journal Article
• Authors: Murall, Carmen Lía; Reyné, Bastien; Selinger, Christian; Bernat, Claire; Boué, Vanina; Grasset, Sophie; Groc, Soraya; Rahmoun, Massilva; Bender, Noemi; Bonneau, Marine; Foulongne, Vincent; Graf, Christelle; Picot, Eric; Picot, Marie-Christine; Tribout, Vincent; Waterboer, Tim; Bravo, Ignacio G; Reynes, Jacques; Segondy, Michel; Boulle, Nathalie; Alizon, Samuel
• Is Part Of: Vaccine. Volume 38:Issue 51(2020)
• Page Start: 8167
• Page End: 8174
• Publication Date: 2020-12-03
• Subjects: HPV -- Vaccination -- Serology -- Cross-protection -- Acute infections -- Genital infections; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.10.078
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Understanding genital infections by Human papillomaviruses (HPVs) remains a major public health issue, especially in countries where vaccine uptake is low. We investigate HPV prevalence and antibody status in 150 women (ages 18 to 25) in Montpellier, France. At inclusion and one month later, cervical swabs, blood samples and questionnaires (for demographics and behavioural variables) were collected. Oncogenic, non-vaccine genotypes HPV51, HPV66, HPV53, and HPV52 were the most frequently detected viral genotypes overall. Vaccination status, which was well-balanced in the cohort, showed the strongest (protective) effect against HPV infections, with an associated odds ratio for alphapapillomavirus detection of 0.45 (95% confidence interval: [0.22;0.58]). We also identified significant effects of age, number of partners, body mass index, and contraception status on HPV detection and on coinfections. Type-specific IgG serological status was also largely explained by the vaccination status. IgM seropositivity was best explained by HPV detection at inclusion only. Finally, we identify a strong significant effect of vaccination on genotype prevalence, with a striking under-representation of HPV51 in vaccinated women. Variations in HPV prevalence correlate with key demographic and behavioural variables. The cross-protective effect of the vaccine against HPV51 merits further investigation.